Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr;48(4):460-471.
doi: 10.1007/s00270-024-03930-7. Epub 2025 Jan 9.

Six-Month Outcomes from the Prospective, Multi-Center, Non-Randomized Clinical Study of the COVERA(™) Arterio VeNous (AV) Stent Graft in the Treatment of Stenosis in the VEnous OutfloW of AV Fistula Access Circuits (AVeNEW PAS)

Bart Dolmatch  1 , Talar Saber  2 , Margo Underwood  3 ; and AVeNEW PAS trial investigators
Collaborators, Affiliations
Clinical Trial

Six-Month Outcomes from the Prospective, Multi-Center, Non-Randomized Clinical Study of the COVERA(™) Arterio VeNous (AV) Stent Graft in the Treatment of Stenosis in the VEnous OutfloW of AV Fistula Access Circuits (AVeNEW PAS)

Bart Dolmatch et al. Cardiovasc Intervent Radiol. 2025 Apr.

Erratum in

Abstract

Purpose: The AVeNEW Post-Approval Study (AVeNEW PAS) follows upon results from the AVeNEW IDE clinical trial and was designed to provide additional clinical evidence of safety and effectiveness using the Covera™ Vascular Covered Stent to treat arteriovenous fistula (AVF) stenoses in a real-world hemodialysis patient population.

Materials and methods: One hundred AVF patients were prospectively enrolled at 11 clinical trial sites in the USA and treated with the covered stent after angioplasty of a clinically significant target stenosis. The primary safety outcome was freedom from any adverse event that suggests the involvement of the AV access circuit evaluated at 30 days. The primary efficacy outcome was Target Lesion Primary Patency (TLPP) at six months, determined by an independent core laboratory. Secondary outcome measures included technical success defined as successful deployment to the intended location and access circuit primary patency (ACPP).

Results: Safety was 94.9% with no device-related deaths nor in-patient hospitalization. Technical success was 100%. TLPP rates at 1, 3, and 6 months were 100, 89.7, and 82.2%. ACPP rates at 1, 3, and 6 months were 98, 76.3, and 60.0%. Target stenoses were 81% restenotic, and 75% located in the cephalic vein arch. There were 35% non-target stenoses treated with angioplasty during the index procedure.

Conclusion: The 6-month results of the AVeNEW PAS confirm results from the AVeNEW IDE clinical trial and demonstrate safety and efficacy using the Covera(™) Covered Stent in a real-world US hemodialysis patient population.

Trial registration: NCT04261686.

Level of evidence: 3 - prospective, multicenter.

Keywords: Angioplasty; Arteriovenous fistula; Dialysis; Hemodialysis; Stent.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: BD reports receiving speaker and consulting fees from Becton Dickinson and Company; Medtronic; and Merit Medical Systems. TS and MU are employees and shareholders in Becton, Dickinson and Company. Ethical approval: All procedures were in accordance with the ethical standards of the institution(s) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Investigators followed a standard protocol approved by their institutional reviews boards (IRB), and all patients provided written informed consent prior to completing any procedure. Consent for publication: For this type of study, consent for publication is not required.

Figures

Fig. 1
Fig. 1
AVeNEW PAS survival analysis of target lesion primary patency (TLPP)* at 6 Months
Fig. 2
Fig. 2
AVeNEW PAS survival analysis of subjects with Access Circuit Primary Patency (ACPP) through 6 Months
See this image and copyright information in PMC

References

    1. Jose MD, et al. Fatal dialysis vascular access hemorrhage. Am J Kidney Dis. 2017;70(4):570–5. - PubMed
    1. Inston N, et al. Aneurysms in vascular access: state of the art and future developments. J Vasc Access. 2017;18(6):464–72. - PubMed
    1. Khawaja AZ, et al. Impact of arteriovenous fistula aneurysms on a UK dialysis populations’ perception of vascular access. BMC Nephrol. 2024;25(1):299. - PMC - PubMed
    1. Lok CE, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–164. - PubMed
    1. Rajput A, et al. Venous aneurysms in autogenous hemodialysis fistulas: is there an association with venous outflow stenosis. J Vasc Access. 2013;14(2):126–30. - PubMed

Associated data